Category TVTX

Travere Therapeutics Inc

Travere Therapeutics ( $TVTX ) after FILSPARI’s FDA approval in FSGS

Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS.

REPL, TVTX, GRCE: three April 2026 PDUFA decisions that matter

A full editorial deep dive on the three most interesting April biotech FDA setups still ahead: Replimune, Travere Therapeutics and Grace Therapeutics. Each story carries a different kind of risk. Replimune is the credibility test after a prior CRL. Travere is the commercial expansion test for a product that already sells. Grace is the classic small-cap binary setup where one approval could change the company’s profile very quickly.

Travere Therapeutics ( $TVTX ) pre-catalyst deep dive PDUFA APR 13 2026

TVTX is not the typical pre-PDUFA biotech where everything depends on one unproven idea and the balance sheet is already screaming for a financing. Travere enters the April 13, 2026 decision with a drug already commercial in the United States, a meaningful revenue base, a still-usable cash position, and a management team that has already taken FILSPARI from accelerated approval to full approval in IgA nephropathy. That matters. It changes the quality of the setup. It means the market is not being asked to price pure hope. It is being asked to decide how much additional franchise value belongs to FILSPARI if the FDA agrees that the FSGS package is strong enough for approval.

TVTX Travere Therapeutics Inc UPDATE jan 13 PDUFA Extension to april 13 2026

Travere confirmed that the PDUFA date for the FILSPARI sNDA in FSGS is January 13, 2026. In the latest corporate update (press release) and at the JPM conference, management explained that the FDA recently sent a series of additional information requests “to further characterize the clinical benefit of FILSPARI” and that Travere has now submitted complete responses, which are under review.

TVTX Travere Therapeutics Inc UPDATE JAN 2

Travere Therapeutics has transitioned in 2025 from a “promising rare-disease biotech” into a genuine kidney franchise story. Filspari is fully approved in IgAN and ramping quickly, while the January 13, 2026 PDUFA on FSGS could make it the first FDA-approved therapy in that indication.

TVTX Travere Therapeutics

Travere Therapeutics is a commercial-stage rare-disease biotech focused on kidney and metabolic disorders. Its lead product, FILSPARI (sparsentan), is approved in the United States for IgA nephropathy (IgAN) and is under FDA review for focal segmental glomerulosclerosis (FSGS). A supplemental NDA for FSGS has an FDA target action date in early 2026, turning TVTX into a classic binary catalyst name with an already meaningful revenue base from IgAN.